Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Apr 7:12:812358.
doi: 10.3389/fonc.2022.812358. eCollection 2022.

Predicting Bone Metastasis Risk Based on Skull Base Invasion in Locally Advanced Nasopharyngeal Carcinoma

Bo Wu  1   2 , Yu Guo  2 , Hai-Hua Yang  3 , Qian-Gang Gao  2 , Ye Tian  1
Affiliations

Predicting Bone Metastasis Risk Based on Skull Base Invasion in Locally Advanced Nasopharyngeal Carcinoma

Bo Wu et al. Front Oncol. .

Abstract

Objective: To develop and validate a bone metastasis prediction model based on skull base invasion (SBI) in patients with locally advanced nasopharyngeal carcinoma (LA-NPC).

Methods: This retrospective cohort study enrolled 290 patients with LA-NPC who received intensity-modulated radiation therapy in two hospitals from 2010 to 2020. Patient characteristics were grouped by SBI and hospital. Both unadjusted and multivariate-adjusted models were used to determine bone metastasis risk based on SBI status. Subgroup analysis was performed to investigate heterogeneity using a forest graph. Cox proportional hazard regression analysis was used to screen for risk factors of bone metastasis-free survival (BMFS). A nomogram of BMFS based on SBI was developed and validated using C-index, receiver operating characteristic curve, calibration curves, and decision curve analysis after Cox proportional hazard regression analysis.

Results: The incidence of bone metastasis was 14.83% (43/290), 20.69% (24/116), and 10.92% (19/174) in the overall population, SBI-positive group, and SBI-negative group, respectively. In the unadjusted model, SBI was associated with reduced BMFS [HR 2.43 (1.32-4.47), P = 0.004], and the results remained stable after three continuous adjustments (P <0.05). No significant interaction was found in the subgroup analyses (P for interaction >0.05). According to Cox proportional hazard regression analysis and clinical value results, potential risk factors included SBI, Karnofsky performance status, TNM stage, induction chemotherapy, concurrent chemoradiotherapy, and adjuvant chemotherapy. Using a training C-index of 0.80 and a validation C-index of 0.79, the nomogram predicted BMFS and demonstrated satisfactory prognostic capability in 2, 3, and 5 years (area under curve: 83.7% vs. 79.6%, 81.7% vs. 88.2%, and 79.0% vs. 93.8%, respectively).

Conclusion: Skull base invasion is a risk factor for bone metastasis in patients with LA-NPC. The SBI-based nomogram model can be used to predict bone metastasis and may assist in identifying LA-NPC patients at the highest risk of bone metastasis.

Keywords: bone metastasis; bone metastasis-free survival; intensity modulated radiation therapy; nasopharyngeal carcinoma; nomogram; prediction model; skull base invasion.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Flow diagram of the study selection process.
Figure 2
Figure 2
Kaplan–Meier Survival Curves for bone metastasis-free survival (A), distant metastasis-free survival, (B) and overall survival (C) of locally advanced nasopharyngeal carcinoma patients based on skull base invasion.
Figure 3
Figure 3
Hazard risk of bone metastasis in subgroup analyses after adjustment for hospital, age, sex, Karnofsky performance status, smoking index, and histological type.
Figure 4
Figure 4
Nomogram predicting 24, 36, and 60 months of bone metastasis-free survival.
Figure 5
Figure 5
ROC curves of the training dataset (A) and the validation dataset (B) in 24 months (AUC: 83.7% vs. 79.6%), 36 months (AUC: 81.7% vs. 88.2%) and 60 months (AUC: 79.0% vs. 93.8%).
Figure 6
Figure 6
Calibration curves of the training dataset (A–C) and the validation dataset (D–F) in 24, 36, and 60 months.
Figure 7
Figure 7
Usefulness evaluation of the training dataset (A–C) and the validation dataset (D–F) in 24, 36, and 60 months.
See this image and copyright information in PMC

References

    1. Chen Y, Chan A, Le Q, Blanchard P, Sun Y, Ma J. Nasopharyngeal Carcinoma. Lancet (London England) (2019) 394(10192):64–80. doi: 10.1016/s0140-6736(19)30956-0 - DOI - PubMed
    1. Ji MF, Sheng W, Cheng WM, Ng MH, Wu BH, Yu X, et al. . Incidence and Mortality of Nasopharyngeal Carcinoma: Interim Analysis of a Cluster Randomized Controlled Screening Trial (PRO-NPC-001) in Southern China. Ann Oncol: Off J Eur Soc Med Oncol (2019) 30(10):1630–7. doi: 10.1093/annonc/mdz231 - DOI - PubMed
    1. Zhang Y, Chen L, Hu GQ, Zhang N, Zhu XD, Yang KY, et al. . Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma. New Engl J Med (2019) 381(12):1124–35. doi: 10.1056/NEJMoa1905287 - DOI - PubMed
    1. Liao S, Xie Y, Feng Y, Zhou Y, Pan Y, Fan J, et al. . Superiority of Intensity-Modulated Radiation Therapy in Nasopharyngeal Carcinoma With Skull-Base Invasion. J Cancer Res Clin Oncol (2020) 146(2):429–39. doi: 10.1007/s00432-019-03067-y - DOI - PMC - PubMed
    1. Caglar M, Ceylan E, Ozyar E. Frequency of Skeletal Metastases in Nasopharyngeal Carcinoma After Initiation of Therapy: Should Bone Scans be Used for Follow-Up? Nucl Med Commun (2003) 24(12):1231–6. doi: 10.1097/00006231-200312000-00005 - DOI - PubMed

LinkOut - more resources